Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by SizzlinSteakson Dec 18, 2017 8:33am

40 Views

Post# 27176647

RE:Big Short position on Kaly! Hold your Share!

This is not the short position. It is the short volume traded. Big difference.

Divineinc wrote: https://shortdata.ca/?c=kalytera-therapeutics%2C%20inc.-short-sales&sym=KALY.V

What do you think of this?

For me, I'm holding my share... I'll be patient for one time :)